pembrolizumab,nivolumab
merck,bms
['melanoma', 'opdivo', 'check,mate,76k', '$bmy', '$mrk']
yesterday $bmy toplined checkmate-76k, opdivo in stage iib/c adjuvant melanoma. x-trial comparison vs $mrk km-716: pfs slightly better hr (0.42)
12mth rfs 89% vs 79%, so pretty much in line
gr3/4 traes 10% vs 2%. 
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.